FDA approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant.
FDA approves first PI3K inhibitor for breast cancer
More from FDA News AlertsMore posts in FDA News Alerts »
- FDA Takes Steps Aimed at Improving Quality, Safety and Efficacy of Sunscreens
- Armstrong Medical Limited Recalls AMSORB PLUS PREFILLED G-CAN 1.0L Due to Reduced Gas Flow to Patients During Anesthesia
- FDA In Brief: FDA Publishes Material Safety Data to Promote Safer, More Effective Medical Devices
- FDA Issues Draft Guidance on Donor Eligibility and Manufacturing of Cellular Therapies for Animals